Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87921 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL22216666 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL60131 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL1828721 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL728754 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL24782761 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21422636 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21057384 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21057351 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL11147768 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135361-A1 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) | 2014-05-15 | — | — | US | claimed |
| EP-2727919-A1 | BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. (CN) | 2014-05-07 | — | — | EP | claimed |
| EP-2727919-B1 | BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO LTD (CN) | 2019-05-08 | — | — | EP | disclosed |
| US-10022362-B2 | Anti-allergy benzocycloheptathiophene derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD (CN) | 2018-07-17 | — | — | US | disclosed |
| US-20160166563-A1 | Anti-Allergy Benzocycloheptathiophene Derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD (CN) | 2016-06-16 | — | — | US | disclosed |
| US-9296731-B2 | Anti-allergy benzocycloheptathiophene derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) | 2016-03-29 | — | — | US | disclosed |
| US-8829030-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2014-09-09 | — | — | US | disclosed |
| US-20140135361-A1 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) | 2014-05-15 | — | — | US | disclosed |
| EP-2727919-A1 | BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. (CN) | 2014-05-07 | — | — | EP | disclosed |
| US-8674118-B2 | Compounds and methods for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130096106-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-04-18 | — | — | US | disclosed |
| US-7569600-B2 | Compounds and methods for the treatment of prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2009-08-04 | — | — | US | disclosed |
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-10-30 | — | — | US | disclosed |
| US-7402608-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-07-22 | — | — | US | disclosed |
| EP-1879879-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Virochem Pharma Inc. (CA) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276533-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-12-07 | — | — | US | disclosed |
| WO-2006119646-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2006-11-16 | — | — | WO | disclosed |
| EP-1569929-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS | Virochem Pharma Inc. (CA) | 2005-09-07 | — | — | EP | disclosed |
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2005-01-13 | — | — | US | disclosed |
| WO-2004052885-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | HTR6 4178/4885PHGDH 2381/4885MGLL 1240/4885 |
| US-20160166563-A1 | Anti-Allergy Benzocycloheptathiophene Derivatives | NR1H4, TST, CYP7A1 | HTR6 1560/4885PHGDH 1017/4885MGLL 2718/4885 |
| US-20130096106-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | ZC3HAV1, ZYX, ZFX | HTR6 4178/4885PHGDH 2381/4885MGLL 1240/4885 |
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | HTR6 4178/4885PHGDH 2381/4885MGLL 1240/4885 |
| US-20140135361-A1 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES | TST, HRH1, ABCB11 | HTR6 1952/4885PHGDH 911/4885MGLL 2558/4885 |
| US-20060276533-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, YBX1, HAX1 | HTR6 3148/4885PHGDH 3443/4885MGLL 1342/4885 |
| US-10022362-B2 | Anti-allergy benzocycloheptathiophene derivatives | NR1H4, TST, CYP7A1 | HTR6 1560/4885PHGDH 1017/4885MGLL 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.